Evaluating the potential of non‐immunosuppressive cyclosporin analogs for targeting Toxoplasma gondii cyclophilin: Insights from structural studies

Toxoplasmosis persists as a prevalent disease, facing challenges from parasite resistance and treatment side effects. Consequently, identifying new drugs by exploring novel protein targets is essential for effective intervention. Cyclosporin A (CsA) possesses antiparasitic activity against Toxoplasm...

Full description

Saved in:
Bibliographic Details
Published inProtein science Vol. 33; no. 10; pp. e5157 - n/a
Main Authors Favretto, Filippo, Jiménez‐Faraco, Eva, Catucci, Gianluca, Di Matteo, Adele, Travaglini‐Allocatelli, Carlo, Sadeghi, Sheila J., Dominici, Paola, Hermoso, Juan A., Astegno, Alessandra
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.10.2024
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Toxoplasmosis persists as a prevalent disease, facing challenges from parasite resistance and treatment side effects. Consequently, identifying new drugs by exploring novel protein targets is essential for effective intervention. Cyclosporin A (CsA) possesses antiparasitic activity against Toxoplasma gondii, with cyclophilins identified as possible targets. However, CsA immunosuppressive nature hinders its use as an antitoxoplasmosis agent. Here, we evaluate the potential of three CsA derivatives devoid of immunosuppressive activity, namely, NIM811, Alisporivir, and dihydrocyclosporin A to target a previously characterized cyclophilin from Toxoplasma gondii (TgCyp23). We determined the X‐ray crystal structures of TgCyp23 in complex with the three analogs and elucidated their binding and inhibitory properties. The high resolution of the structures revealed the precise positioning of ligands within the TgCyp23 binding site and the details of protein–ligand interactions. A comparison with the established ternary structure involving calcineurin indicates that substitutions at position 4 in CsA derivatives prevent calcineurin binding. This finding provides a molecular explanation for why CsA analogs can target Toxoplasma cyclophilins without compromising the human immune response.
Bibliography:John Kuriyan
Review Editor
Filippo Favretto and Eva Jiménez‐Faraco authors contributed equally.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Review Editor: John Kuriyan
ISSN:0961-8368
1469-896X
1469-896X
DOI:10.1002/pro.5157